Company intelligence / Profile preview
Monte Rosa Therapeutics
Boston, Massachusetts, United Statesmonterosatx.com ↗
- Ownership
- Public · GLUE
- Employees
- ~100
- Development stage
- Phase 1
01
Overview
MRT-6160 Phase 1 study showed deep VAV1 degradation of >90%, significant T and B cell functional inhibition, and favorable safety profile. MRT-2359 Phase 1/2 study demonstrated encouraging signals of clinical response in castration-resistant prostate cancer patients resistant to AR therapy, including confirmed RECIST response[10].
- Therapeutic areas
- OncologyImmunologyNeurology
- Modalities
- Molecular glue degraders (MGDs)
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
03
Partnerships
Novartis (global development and commercialization license agreement for VAV1-directed molecular glue degraders including MRT-6160)Roche (strategic collaboration to discover and develop MGDs against targets in cancer and neurological diseases)
04
Financials
- Market cap
- $874.5M
- Total revenue
- $123.7M
- Enterprise value
- $333M
Beyond the preview
Go deeper on Monte Rosa Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Monte Rosa Therapeutics.